Explore ViiV Healthcare

I am a

... looking for

US News

News
Company Statements

ViiV Healthcare presents positive proof-of-concept findings for GSK3640254, a novel, investigational maturation inhibitor for the treatment of HIV

09 Mar 2021
ViiV Healthcare presents data for long-acting cabotegravir and rilpivirine for the treatment of HIV showing continued virologic suppression to 96 weeks

06 Mar 2021
ViiV Healthcare to present new data on long-acting regimens for HIV prevention and treatment, alongside pipeline advances at CROI 2021

02 Mar 2021
ViiV Healthcare Builds on accelerate Initiative, Extending Community-Centered Approach Nationally to Disrupt Disparities in Care for Black Same-Gender-Loving Men Living With HIV

25 Feb 2021
ViiV Healthcare Submits Supplemental New Drug Application to US FDA for Expanded Use of Cabenuva (cabotegravir, rilpivirine) as an HIV Treatment for Use Every 2-Months

24 Feb 2021
ViiV Healthcare announces FDA approval of Cabenuva (cabotegravir, rilpivirine), the first and only complete long-acting regimen for HIV treatment

21 Jan 2021

ViiV Healthcare COVID-19 Community Emergency Response Fund

27 Apr 2020
ViiV Healthcare ranks #1 company in the PatientView ‘Corporate Reputation of Pharma – from the Patient Perspective 2019 – 2020’ survey

21 Apr 2020
ViiV Healthcare’s commitment to support AIDS2020 and key conferences during COVID-19 outbreak

30 Mar 2020
COVID-19 Guidance to Investigators

27 Mar 2020
Our Response to COVID-19

16 Mar 2020

Website images are not intended to imply that the models pictured have HIV.

©2018 ViiV Healthcare group of companies. All rights reserved. ViiV Healthcare US, Five Moore Drive, Research Triangle Park, North Carolina USA, 27709-3398.

Connect with us